Biosyntia is a biotech startup within synthetic biology and metabolic engineering. Biosyntia develops biocatalysts at an unprecedented speed and efficiency by employing a patent pending high-throughput screening technology.
Lysogene SA is a leading gene therapy biotechnology company developing breakthrough treatments targeting severe genetic pathologies with Central Nervous System involvement and high unmet medical needs.
Lysogene has successfully completed a Phase 1/2 gene therapy study using its lead product in patients with Sanfilippo syndrome, which is a lethal pediatric neurodegenerative disorder with currently no treatment. It belongs to the group of Lysosomal Storage Disorders and affects 1:100,000 live births.
RSPR Pharma is a Swedish pharmaceutical company developing an oral anti-asthmatic drug providing mast cell control by inhibiting both induced and basal release of asthma mediators.
Asthma is an inflammatory condition affecting some 300 million people worldwide and despite gold standard therapy (inhaled corticosteroids, which do not target mast cells) only 50% of patients reach asthma control. The RSPR Pharma compound is currently in clinical development and is intended for patients not controlled by corticosteroids.